Advanced Cell announces ruling on human applications of nuclear transfer, issuance of patent, and intent to appeal adverse ruling on animal claims.Advanced Cell Technology, Inc. (Worcester, MA) announced the decision of the Board of Patent Appeals and Interference, interference number 105,192, between itself and Geron Corporation over methods of producing cultured inner cell mass in·ner cell mass n. The mass at the embryonic pole of the blastocyst concerned with the formation of the body of the embryo. (CICM CICM Continuous Inductor Current Mode CICM Certified International Configuration Manager (International Society of Configuration Management) CICM Missionhurst, Congregation of the Immaculate Heart of Mary ) cells, often referred to as embryonic stem cells. The Board granted ACT's motion to remove from the interference its patent claim relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the human species, affirming in its decision that "this claim is not properly before us." In a second aspect of the decision of the Board of Patent Appeals and Interference ruled against ACT and in favor of Geron on other motions relating to the cloning of non-human animal embryos and CICM cells. ACT intends to appeal this decision. ACT also announces the issuance of an important United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patent relating to the use of nuclear transfer in regenerative medicine, United States Patent 6,808,704, titled "Method for Generating Immune-Compatible Cells and Tissues Using Nuclear Transfer Techniques". That patent is completely unrelated to the animal cloning patents involved in the interference proceedings with Geron. "Advanced Cell Technology is focused on the human medical applications of stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. technology. It has been our contention all along that this interference relates to patent claims for non-human animal cloning and therefore does not relate to our core human product focus. This ruling makes our point for us," said William M. Caldwell, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Cell Technology. "However, we have numerous commercial partners utilizing ACT's patented animal cloning technology and we intend to defend our patents vigorously. We intend to appeal the decision relating to the animal cloning claims." Dr. Michael D. West Dr. Michael D. West is an entrepreneurial scientist and visionary [1] [2] [3] [4] who has led progress in anti-aging and biotechnology. He is CEO of BioTime, Inc. , Chairman, President, and Chief Scientific Officer of ACT commented on the issuance of United States Patent 6,808,704 saying: "Regenerative medicine is a technology with many potential human applications. Yet unlike many advances in the past, regenerative medicine demands many new research tools. Our new patent provides one such tool, facilitating the testing of cells and tissue-engineered constructs." ACT is a biotechnology company applying human stem cell technology in the emerging field of regenerative medicine. Advanced Cell Technology, Inc. +1-508-756-1212 www.advancedcell.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion